GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

SK Bioscience Co 302440.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

40,400

+5.21%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About SK Bioscience Co

Its shares trade on KRX under the ticker 302440.KS. It has been listed since 18 March 2021. In the fiscal year to 31 December 2025, it reported revenue of ₩651.37bn and a net loss of ₩57.42bn. At that date it held total assets of ₩2.96trn and shareholders' equity of ₩1.79trn.

SK bioscience Co., Ltd. engages in the development and distribution of bio and vaccine products. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2021-03-18. The firm's main products include vaccines such as SKYCellflu and Rotatech. The firm also sells infusion solutions. In addition, the Company engages in technology export business. The firm sells its products in domestic and overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
18 Mar 2021
Employees
1,067

Leadership

Pay as last reported

  • Mr. Jae Yong AhnPresident, Chief Executive Officer, Director, since 2018₩703.0m
  • Mr. Jae Seon HwangChief Information Security Officer
  • Mr. Jong Su ParkChief Privacy Officer
  • Mr. Hun KimDirector, since 2018₩922.0m
  • Mr. Jae Hyeon AhnOther Non-Executive Director
  • Mr. Jeong Wuk ChoiNon-Executive Independent Director
  • Mr. Yik Hwan GwonNon-Executive Independent Director
  • Mr. Chang Jin MoonNon-Executive Independent Director
  • Mr. Seon Hyeon ParkNon-Executive Independent Director
  • Mr. Jae Yeong ChoiIR Contact Officer, since 2024

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
75
Environment
75
Social
99
Governance
52
Direct emissions (scope 1)
5,173 t
Energy emissions (scope 2)
13,320 t
Value chain emissions (scope 3)
112,381 t
Women in the workforce
39%
Carbon reduction policy
Yes
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Seongnam, Gyeonggi-Do
  • Offers vaccines including SKYCellflu and Rotatech
  • Engages in technology export business

Weaknesses

  • No specific weaknesses mentioned in the provided data
  • No information on market share or competitive position
  • No details on financial performance or product development pipeline

Opportunities

  • Expanding domestic and overseas markets for products
  • Potential growth in biotechnology sector
  • Technology export business could expand

Threats

  • No specific threats mentioned in the provided data
  • No information on regulatory challenges or competition
  • No details on potential market risks or economic factors

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.